# OnCo record paper-zuma-1-axi-cel-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-zuma-1-axi-cel-nejm-2017" ;
schema:name "ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma"@en ;
schema:description "In lymphoma refractory to chemotherapy, where expected survival was around six months, a single CAR-T infusion produced responses in 82% of patients and long-term remission in about 40%."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , ;
schema:sameAs ;
schema:datePublished "2017"^^xsd:gYear ;
schema:author "Neelapu SS, Locke FL, Bartlett NL, et al." ;
onco:related , , , ;
onco:cancers , ;
onco:technologies ;
onco:targets ;
onco:drugs ;
onco:companies ;
onco:institutions , ;
onco:terms , , ;
onco:trials ;
onco:people ;
onco:bottlenecks , ;
onco:journals .